| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/27/2007 | US7183253 Substantially pure glycopeptide antibiotics AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 |
| 02/27/2007 | US7183251 hCG therapy for the treatment of breast cancer |
| 02/27/2007 | US7183238 microbicides, pesticides and herbicides |
| 02/27/2007 | US7183112 Administering locally to the area of inflammation to an animal an anti-inflammatory effective amount of an anti-malaria compound which is aminoquinoline or derivative |
| 02/27/2007 | US7183111 Immunomodulatory formulations and methods for use thereof |
| 02/27/2007 | US7183105 Eubacterial minicells and their use as vectors for nucleic acid delivery and expression |
| 02/27/2007 | US7183101 NCC2705—the genome of a bifidobacterium |
| 02/27/2007 | US7183095 Cell culture system for synthesis of infectious hepatitis C virus |
| 02/27/2007 | US7183075 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 02/27/2007 | US7183054 Glyceraldehyde-3-phosphate dehydrogenase and Saframycin A/dna complexes; evaluation of microbiocidal and antiproliferative activity |
| 02/27/2007 | US7183045 Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution |
| 02/27/2007 | US7182971 Comprising 15-70% by weight of diglycerides in which less than 15% by weight of constitutive fatty acids are omega 3 type unsaturated fatty acids, and 30-85% by weight of a triglyceride in which at least 15% by weight of constitutive fatty acids are omega 3 type; for oral medicinal formulations and foods |
| 02/27/2007 | US7182968 Composition containing xylitol and fiber |
| 02/27/2007 | US7182963 Cosmetic and dermopharmaceutical compositions for skin prone to acne |
| 02/27/2007 | US7182962 Swine plasma albumin; gene expression of immunostimulant; prevent infections; anticancer agents |
| 02/27/2007 | US7182960 Pharmaceutical compositions for nasal delivery of oestradiol and norethisterone |
| 02/27/2007 | US7182959 Preparing powder consisting of active substance and all other ingredients of solid dosage form, dispensing solvent solution or dispersion in mold, putting compacted powder on top of liquid in mold, desolventizing |
| 02/27/2007 | US7182958 With oral bioavailability; tadalafil; erectile dysfunction |
| 02/27/2007 | US7182956 Entrapping in phosphatidylcholine component; room temperature transdermal delivery system; long shelf life |
| 02/27/2007 | US7182955 Abuse-resistant transdermal dosage form |
| 02/27/2007 | US7182953 Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| 02/27/2007 | US7182949 Composition comprising vitamin C prepared during application, use of enzymes for forming vitamin C for topical use, and a cosmetic treatment method |
| 02/27/2007 | US7182948 Topical veterinary compositions and methods for the treatment and prevention of infection |
| 02/27/2007 | US7182199 Systems, methods and apparatuses for manufacturing dosage forms |
| 02/27/2007 | CA2432798C Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 02/27/2007 | CA2425849C Angiostatic steroids |
| 02/27/2007 | CA2240281C Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases |
| 02/27/2007 | CA2168517C Substituted thiophenylsulfonylureas and -thioureas processes for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 02/26/2007 | CA2557377A1 Mucosal delivery tablet |
| 02/26/2007 | CA2517313A1 Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
| 02/23/2007 | WO2007021308A1 Metabotropic glutamate-receptor-potentiating isoindolones |
| 02/22/2007 | WO2007022541A2 Method of treating dry eye disease with non-drying antihistamines |
| 02/22/2007 | WO2007022535A2 Prodrugs of active agents |
| 02/22/2007 | WO2007022532A2 Cyclopropyl compounds and compositions for delivering active agents |
| 02/22/2007 | WO2007022529A2 Method of treating inflammatory diseases |
| 02/22/2007 | WO2007022523A2 Methods to enhance chemotherapy |
| 02/22/2007 | WO2007022509A2 Use of seh inhibitors as analgesics |
| 02/22/2007 | WO2007022502A2 Bridged n-cyclic sulfonamido inhibitors of gamma secretase |
| 02/22/2007 | WO2007022501A2 Useful indole compounds |
| 02/22/2007 | WO2007022488A2 Crystalline rosuvastatin intermediate |
| 02/22/2007 | WO2007022453A2 Active aromatic sulfonamide organic compounds and biocidal uses thereof |
| 02/22/2007 | WO2007022443A2 Systemic and intrathecal effects of a novel series of phospholipase a2 inhibitors on hyperalgesia and spinal pge2 release |
| 02/22/2007 | WO2007022437A2 Therapeutic agents for the treatment of cancer and metabolic disorders |
| 02/22/2007 | WO2007022435A2 Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| 02/22/2007 | WO2007022434A2 Anti-inflammatory activity of phenethylisothiocyanate (peitc) and the barbarea verna seed preparation containing this compound |
| 02/22/2007 | WO2007022433A2 SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL |
| 02/22/2007 | WO2007022427A2 Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
| 02/22/2007 | WO2007022408A2 Combination methods of saha and targretin for treating cancer |
| 02/22/2007 | WO2007022377A2 Conformable solvent-based bandage and coating material |
| 02/22/2007 | WO2007022371A2 Chemokine receptor binding compounds |
| 02/22/2007 | WO2007022356A2 Drug-surfactant complexes for sustained release |
| 02/22/2007 | WO2007022351A2 Muscarinic acetylcholine receptor antagonists |
| 02/22/2007 | WO2007022345A2 Vitamin b12 nasal spray and method of use |
| 02/22/2007 | WO2007022344A2 Methods and compositions for the preventioin and treatment of kidney disease |
| 02/22/2007 | WO2007022331A2 Method of treating a subject suffering from degenerative disc disease using a nitric oxide synthase inhibitor |
| 02/22/2007 | WO2007022320A2 Bacterial contact inhibition and methods thereof |
| 02/22/2007 | WO2007022305A2 2-aminoimidazopyridines for treating neurodegenerative diseases |
| 02/22/2007 | WO2007022280A1 Phosphodiesterase 10 inhibitors |
| 02/22/2007 | WO2007022268A2 Compounds and compositions as protein kinase inhibitors |
| 02/22/2007 | WO2007022258A1 Novel high affinity thiophene-based and furan-based kinase ligands |
| 02/22/2007 | WO2007022257A2 Monocyclic and bicyclic compounds and methods of use |
| 02/22/2007 | WO2007022225A2 Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| 02/22/2007 | WO2007022182A1 Neurorestoration with r(+) pramipexole |
| 02/22/2007 | WO2007022173A2 Crystalline forms fenoldopam mesylate |
| 02/22/2007 | WO2007022138A2 Genistein inhibition of transthyretin amyloidosis |
| 02/22/2007 | WO2007022121A2 O-nitro compounds, pharmaceutical compositons thereof and uses thereof |
| 02/22/2007 | WO2007022102A2 Pentacyclic kinase inhibitors |
| 02/22/2007 | WO2007022082A2 Vector delivery-based microbicides |
| 02/22/2007 | WO2007022077A2 Hoof repair material |
| 02/22/2007 | WO2007022076A2 Prevention of neurodegeneration by macrolide antibiotics |
| 02/22/2007 | WO2007022073A2 Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| 02/22/2007 | WO2007022068A1 Olanzapine analogs and methods of use thereof |
| 02/22/2007 | WO2007022061A2 Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
| 02/22/2007 | WO2007022059A2 Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof |
| 02/22/2007 | WO2007022041A2 Mutations and polymorphisms of hdac3 |
| 02/22/2007 | WO2007021991A2 Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| 02/22/2007 | WO2007021990A2 Melanocortin receptor-specific piperazine compounds with diamine groups |
| 02/22/2007 | WO2007021982A2 Modulators of cystic fibrosis transmembrane conductance regulator |
| 02/22/2007 | WO2007021968A2 Sustained release antihistamine and decongestant composition |
| 02/22/2007 | WO2007021966A1 Pyrazole compounds that modulate hsp90 activity |
| 02/22/2007 | WO2007021957A2 Fluorotaxoids |
| 02/22/2007 | WO2007021941A2 Inhibitors of voltage-gated sodium channels |
| 02/22/2007 | WO2007021933A2 Methods and compositions for use in treating vascular diseases and conditions |
| 02/22/2007 | WO2007021897A1 Analogs of salinosporamide a |
| 02/22/2007 | WO2007021881A1 Bis(thio-hydrazide amide) formulation |
| 02/22/2007 | WO2007021877A1 Imidazole compounds that modulate hsp90 activity |
| 02/22/2007 | WO2007021858A2 Methods of making radiolabeled tracers and precursors thereof |
| 02/22/2007 | WO2007021852A2 Transplatinum complexes with n2o2 donor sets as cytotoxic and antitumor agents |
| 02/22/2007 | WO2007021839A2 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| 02/22/2007 | WO2007021825A2 Treatment of proliferative disorders |
| 02/22/2007 | WO2007021803A1 Compounds for the treatment of inflammatory disorders |
| 02/22/2007 | WO2007021794A1 Substituted imidazole compounds as ksp inhibitors |
| 02/22/2007 | WO2007021793A1 Macrocyclic diaminopropanes as beta-secretase inhibitors |
| 02/22/2007 | WO2007021789A1 Modified green tea polyphenol formulations |
| 02/22/2007 | WO2007021754A2 Diltiazem controlled release formulation and method of manufacture |
| 02/22/2007 | WO2007021735A2 Use of phospholipid arachidonic acids for increasing muscle mass in humans |
| 02/22/2007 | WO2007021721A2 Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
| 02/22/2007 | WO2007021710A1 Heterobicyclic compounds useful as p38 kinase inhibiting agents |
| 02/22/2007 | WO2007021694A2 Protein kinase modulation by hops and acacia products |
| 02/22/2007 | WO2007021682A1 Method of use of deacetylase inhibitors |